KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Common Equity (2018 - 2025)

Esperion Therapeutics' Common Equity history spans 8 years, with the latest figure at -$302.0 million for Q4 2025.

  • For Q4 2025, Common Equity rose 22.32% year-over-year to -$302.0 million; the TTM value through Dec 2025 reached -$302.0 million, up 22.32%, while the annual FY2025 figure was -$302.0 million, 22.32% up from the prior year.
  • Common Equity reached -$302.0 million in Q4 2025 per ESPR's latest filing, up from -$451.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of -$196.9 million in Q4 2021 to a low of -$455.0 million in Q4 2023.
  • Average Common Equity over 5 years is -$343.5 million, with a median of -$336.9 million recorded in 2023.
  • Peak YoY movement for Common Equity: crashed 4148.05% in 2021, then grew 22.32% in 2025.
  • A 5-year view of Common Equity shows it stood at -$196.9 million in 2021, then crashed by 64.4% to -$323.8 million in 2022, then plummeted by 40.53% to -$455.0 million in 2023, then grew by 14.57% to -$388.7 million in 2024, then rose by 22.32% to -$302.0 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Common Equity are -$302.0 million (Q4 2025), -$451.4 million (Q3 2025), and -$433.5 million (Q2 2025).